You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The scientists received backing in the form of a €2.4 million EU grant this month and have founded a company, called Biopix-T, to commercialize the platform.
The effort is one of 23 research projects selected as part of a new, €128 million EU package to combat COVID-19.
Antelope is currently developing a urine-based at-home test for the sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae.
The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.
The test was selected for accelerated development and commercialization support by the NIH through the RADx Tech program for COVID-19 diagnostics.
The new funding opportunities come as part of the NIH's Rapid Acceleration of Diagnostics program, which aims to support SARS-CoV-2 testing technologies.
The test will comprise a smartphone-powered single-use, disposable device that detects active SARS-CoV-2 infection based on the presence of viral proteins.
The Boston-based startup will use the funding to flesh out its diagnostic platform to detect antibiotic-resistant bacterial infections within a clinically relevant timeframe.
The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.
The multiplex assay is designed to detect both the SARS-CoV-2 nucleocapsid protein from nasal swabs and patient-derived antibodies against the viral spike protein 1 from blood drops.